Does the media prefer PRGO or SUPN?

In the previous week, Supernus Pharmaceuticals had 2 more articles in the media than Perrigo. MarketBeat recorded 3 mentions for Supernus Pharmaceuticals and 1 mentions for Perrigo. Supernus Pharmaceuticals' average media sentiment score of 0.28 beat Perrigo's score of -0.26 indicating that Supernus Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Perrigo 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Supernus Pharmaceuticals 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer PRGO or NKTR?

In the previous week, Nektar Therapeutics had 8 more articles in the media than Perrigo. MarketBeat recorded 9 mentions for Nektar Therapeutics and 1 mentions for Perrigo. Nektar Therapeutics' average media sentiment score of 0.66 beat Perrigo's score of -0.26 indicating that Nektar Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Perrigo 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Nektar Therapeutics 6 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is OMER or PRGO more profitable?

Omeros has a net margin of 0.00% compared to Perrigo's net margin of -43.50%. Perrigo's return on equity of 9.96% beat Omeros' return on equity. Company Net Margins Return on Equity Return on Assets Omeros N/A -102.16% 64.87% Perrigo -43.50% 9.96% 3.90%

Does the media prefer OMER or PRGO?

In the previous week, Omeros had 2 more articles in the media than Perrigo. MarketBeat recorded 3 mentions for Omeros and 1 mentions for Perrigo. Omeros' average media sentiment score of 0.88 beat Perrigo's score of -0.26 indicating that Omeros is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Omeros 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Perrigo 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Perrigo (PRGO) Competitors

$9.50 -0.10 (-1.04%)

Closing price 03:58 PM Eastern

Extended Trading

$9.64 +0.14 (+1.43%)

As of 07:56 PM Eastern

Compare

PRGO vs. SUPN, NKTR, PCRX, OMER, and ASMB

Should you buy Perrigo stock or one of its competitors? MarketBeat compares Perrigo with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Perrigo include Supernus Pharmaceuticals (SUPN), Nektar Therapeutics (NKTR), Pacira BioSciences (PCRX), Omeros (OMER), and Assembly Biosciences (ASMB). These companies are all part of the "pharmaceuticals" industry.

How does Perrigo compare to Supernus Pharmaceuticals?

Perrigo (NYSE:PRGO) and Supernus Pharmaceuticals (NASDAQ:SUPN) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, earnings, profitability, institutional ownership, media sentiment and valuation.

Supernus Pharmaceuticals has a net margin of -3.74% compared to Perrigo's net margin of -43.50%. Supernus Pharmaceuticals' return on equity of 13.07% beat Perrigo's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Perrigo	-43.50%	9.96%	3.90%
Supernus Pharmaceuticals	-3.74%	13.07%	9.66%

Perrigo presently has a consensus price target of $19.33, indicating a potential upside of 103.51%. Supernus Pharmaceuticals has a consensus price target of $62.17, indicating a potential upside of 39.76%. Given Perrigo's higher possible upside, research analysts plainly believe Perrigo is more favorable than Supernus Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Perrigo	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Supernus Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

In the previous week, Supernus Pharmaceuticals had 2 more articles in the media than Perrigo. MarketBeat recorded 3 mentions for Supernus Pharmaceuticals and 1 mentions for Perrigo. Supernus Pharmaceuticals' average media sentiment score of 0.28 beat Perrigo's score of -0.26 indicating that Supernus Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Perrigo	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Supernus Pharmaceuticals	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

95.9% of Perrigo shares are owned by institutional investors. 0.4% of Perrigo shares are owned by insiders. Comparatively, 8.5% of Supernus Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Supernus Pharmaceuticals has lower revenue, but higher earnings than Perrigo. Supernus Pharmaceuticals is trading at a lower price-to-earnings ratio than Perrigo, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Perrigo	$4.25B	0.31	-$1.43B	-$13.10	N/A
Supernus Pharmaceuticals	$718.95M	3.59	-$38.55M	-$0.51	N/A

Perrigo has a beta of 0.51, suggesting that its share price is 49% less volatile than the broader market. Comparatively, Supernus Pharmaceuticals has a beta of 0.55, suggesting that its share price is 45% less volatile than the broader market.

Summary

Supernus Pharmaceuticals beats Perrigo on 12 of the 16 factors compared between the two stocks.

How does Perrigo compare to Nektar Therapeutics?

Perrigo (NYSE:PRGO) and Nektar Therapeutics (NASDAQ:NKTR) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, media sentiment, profitability, earnings, institutional ownership and dividends.

Perrigo presently has a consensus target price of $19.33, indicating a potential upside of 103.51%. Nektar Therapeutics has a consensus target price of $149.63, indicating a potential upside of 124.36%. Given Nektar Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Nektar Therapeutics is more favorable than Perrigo.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Perrigo	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Nektar Therapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73

Perrigo has a net margin of -43.50% compared to Nektar Therapeutics' net margin of -284.18%. Perrigo's return on equity of 9.96% beat Nektar Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Perrigo	-43.50%	9.96%	3.90%
Nektar Therapeutics	-284.18%	-85.40%	-39.99%

95.9% of Perrigo shares are owned by institutional investors. Comparatively, 75.9% of Nektar Therapeutics shares are owned by institutional investors. 0.4% of Perrigo shares are owned by company insiders. Comparatively, 2.5% of Nektar Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Nektar Therapeutics has lower revenue, but higher earnings than Perrigo. Nektar Therapeutics is trading at a lower price-to-earnings ratio than Perrigo, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Perrigo	$4.25B	0.31	-$1.43B	-$13.10	N/A
Nektar Therapeutics	$55.23M	40.80	-$164.08M	-$8.42	N/A

In the previous week, Nektar Therapeutics had 8 more articles in the media than Perrigo. MarketBeat recorded 9 mentions for Nektar Therapeutics and 1 mentions for Perrigo. Nektar Therapeutics' average media sentiment score of 0.66 beat Perrigo's score of -0.26 indicating that Nektar Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Perrigo	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Nektar Therapeutics	6 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Perrigo has a beta of 0.51, suggesting that its share price is 49% less volatile than the broader market. Comparatively, Nektar Therapeutics has a beta of 1.13, suggesting that its share price is 13% more volatile than the broader market.

Summary

Nektar Therapeutics beats Perrigo on 10 of the 16 factors compared between the two stocks.

How does Perrigo compare to Pacira BioSciences?

Perrigo (NYSE:PRGO) and Pacira BioSciences (NASDAQ:PCRX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, valuation, risk, earnings, media sentiment, institutional ownership and dividends.

Pacira BioSciences has a net margin of 0.70% compared to Perrigo's net margin of -43.50%. Pacira BioSciences' return on equity of 10.24% beat Perrigo's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Perrigo	-43.50%	9.96%	3.90%
Pacira BioSciences	0.70%	10.24%	5.47%

Perrigo currently has a consensus price target of $19.33, suggesting a potential upside of 103.51%. Pacira BioSciences has a consensus price target of $29.40, suggesting a potential upside of 25.05%. Given Perrigo's higher probable upside, research analysts clearly believe Perrigo is more favorable than Pacira BioSciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Perrigo	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Pacira BioSciences	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29

Perrigo has a beta of 0.51, indicating that its stock price is 49% less volatile than the broader market. Comparatively, Pacira BioSciences has a beta of 0.29, indicating that its stock price is 71% less volatile than the broader market.

95.9% of Perrigo shares are held by institutional investors. Comparatively, 99.7% of Pacira BioSciences shares are held by institutional investors. 0.4% of Perrigo shares are held by company insiders. Comparatively, 6.4% of Pacira BioSciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, Perrigo had 1 more articles in the media than Pacira BioSciences. MarketBeat recorded 1 mentions for Perrigo and 0 mentions for Pacira BioSciences. Pacira BioSciences' average media sentiment score of 1.67 beat Perrigo's score of -0.26 indicating that Pacira BioSciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Perrigo	Neutral
Pacira BioSciences	Very Positive

Pacira BioSciences has lower revenue, but higher earnings than Perrigo. Perrigo is trading at a lower price-to-earnings ratio than Pacira BioSciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Perrigo	$4.25B	0.31	-$1.43B	-$13.10	N/A
Pacira BioSciences	$726.41M	1.27	$7.03M	$0.12	195.92

Summary

Pacira BioSciences beats Perrigo on 12 of the 16 factors compared between the two stocks.

How does Perrigo compare to Omeros?

Omeros (NASDAQ:OMER) and Perrigo (NYSE:PRGO) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, profitability, dividends, risk, analyst recommendations and media sentiment.

Omeros has a beta of 2.52, meaning that its stock price is 152% more volatile than the broader market. Comparatively, Perrigo has a beta of 0.51, meaning that its stock price is 49% less volatile than the broader market.

In the previous week, Omeros had 2 more articles in the media than Perrigo. MarketBeat recorded 3 mentions for Omeros and 1 mentions for Perrigo. Omeros' average media sentiment score of 0.88 beat Perrigo's score of -0.26 indicating that Omeros is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Omeros	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Perrigo	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Omeros currently has a consensus price target of $40.33, suggesting a potential upside of 284.86%. Perrigo has a consensus price target of $19.33, suggesting a potential upside of 103.51%. Given Omeros' stronger consensus rating and higher possible upside, equities research analysts clearly believe Omeros is more favorable than Perrigo.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Omeros	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	2.83
Perrigo	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

48.8% of Omeros shares are held by institutional investors. Comparatively, 95.9% of Perrigo shares are held by institutional investors. 10.5% of Omeros shares are held by insiders. Comparatively, 0.4% of Perrigo shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Omeros has a net margin of 0.00% compared to Perrigo's net margin of -43.50%. Perrigo's return on equity of 9.96% beat Omeros' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Omeros	N/A	-102.16%	64.87%
Perrigo	-43.50%	9.96%	3.90%

Omeros has higher earnings, but lower revenue than Perrigo. Perrigo is trading at a lower price-to-earnings ratio than Omeros, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Omeros	N/A	N/A	-$3.35M	$0.70	14.97
Perrigo	$4.25B	0.31	-$1.43B	-$13.10	N/A

Summary

Omeros beats Perrigo on 13 of the 16 factors compared between the two stocks.

How does Perrigo compare to Assembly Biosciences?

Perrigo (NYSE:PRGO) and Assembly Biosciences (NASDAQ:ASMB) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability and risk.

Assembly Biosciences has lower revenue, but higher earnings than Perrigo. Assembly Biosciences is trading at a lower price-to-earnings ratio than Perrigo, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Perrigo	$4.25B	0.31	-$1.43B	-$13.10	N/A
Assembly Biosciences	$72.30M	5.89	-$6.12M	-$0.11	N/A

Perrigo presently has a consensus price target of $19.33, indicating a potential upside of 103.51%. Assembly Biosciences has a consensus price target of $44.00, indicating a potential upside of 64.18%. Given Perrigo's higher probable upside, equities research analysts clearly believe Perrigo is more favorable than Assembly Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Perrigo	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Assembly Biosciences	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Assembly Biosciences has a net margin of -8.98% compared to Perrigo's net margin of -43.50%. Perrigo's return on equity of 9.96% beat Assembly Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Perrigo	-43.50%	9.96%	3.90%
Assembly Biosciences	-8.98%	-4.21%	-3.14%

95.9% of Perrigo shares are owned by institutional investors. Comparatively, 19.9% of Assembly Biosciences shares are owned by institutional investors. 0.4% of Perrigo shares are owned by insiders. Comparatively, 5.1% of Assembly Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Perrigo and Perrigo both had 1 articles in the media. Perrigo's average media sentiment score of -0.26 beat Assembly Biosciences' score of -1.00 indicating that Perrigo is being referred to more favorably in the media.

Company	Overall Sentiment
Perrigo	Neutral
Assembly Biosciences	Negative

Perrigo has a beta of 0.51, suggesting that its share price is 49% less volatile than the broader market. Comparatively, Assembly Biosciences has a beta of 1.07, suggesting that its share price is 7% more volatile than the broader market.

Summary

Assembly Biosciences beats Perrigo on 8 of the 15 factors compared between the two stocks.

Get Perrigo News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PRGO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PRGO vs. The Competition

Export

Metric	Perrigo	MED PRODUCTS Industry	Medical Sector	NYSE Exchange
Market Cap	$1.33B	$8.08B	$6.45B	$23.27B
Dividend Yield	12.08%	2.60%	2.69%	4.07%
P/E Ratio	-0.73	15.24	24.92	31.08
Price / Sales	0.31	6.98	529.01	21.85
Price / Cash	1.81	16.83	44.82	24.45
Price / Book	0.45	3.21	10.79	4.64
Net Income	-$1.43B	$226.25M	$3.56B	$1.07B
7 Day Performance	-10.87%	-3.57%	1.67%	-1.04%
1 Month Performance	-15.23%	-3.72%	0.43%	0.18%
1 Year Performance	-64.06%	1.93%	32.84%	24.25%

Perrigo Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PRGO Perrigo	3.79 of 5 stars	$9.50 -1.0%	$19.33 +103.5%	-63.8%	$1.33B	$4.25B	N/A	8,100
SUPN Supernus Pharmaceuticals	3.1165 of 5 stars	$43.86 -1.2%	$62.17 +41.7%	+37.8%	$2.58B	$718.95M	N/A	580	News Coverage
NKTR Nektar Therapeutics	2.7012 of 5 stars	$61.15 +3.0%	$149.63 +144.7%	+672.0%	$2.01B	$55.23M	N/A	220	News Coverage Gap Down
PCRX Pacira BioSciences	4.2147 of 5 stars	$22.74 -1.1%	$29.40 +29.3%	-6.3%	$904.61M	$726.41M	189.52	720
OMER Omeros	3.7757 of 5 stars	$9.33 +6.9%	$40.33 +332.3%	+221.8%	$632.20M	N/A	13.33	210

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:PRGO) was last updated on 6/23/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Perrigo (PRGO) Competitors

PRGO vs. SUPN, NKTR, PCRX, OMER, and ASMB

How does Perrigo compare to Supernus Pharmaceuticals?

Summary

How does Perrigo compare to Nektar Therapeutics?

Summary

How does Perrigo compare to Pacira BioSciences?

Summary

How does Perrigo compare to Omeros?

Summary

How does Perrigo compare to Assembly Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRGO vs. The Competition

Perrigo Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Perrigo (PRGO) Competitors

PRGO vs. SUPN, NKTR, PCRX, OMER, and ASMB

How does Perrigo compare to Supernus Pharmaceuticals?

Is PRGO or SUPN more profitable?

Do analysts prefer PRGO or SUPN?

Does the media prefer PRGO or SUPN?

Do institutionals and insiders believe in PRGO or SUPN?

Which has preferable earnings and valuation, PRGO or SUPN?

Which has more risk & volatility, PRGO or SUPN?

Summary

How does Perrigo compare to Nektar Therapeutics?

Do analysts prefer PRGO or NKTR?

Is PRGO or NKTR more profitable?

Do institutionals & insiders believe in PRGO or NKTR?

Which has stronger valuation and earnings, PRGO or NKTR?

Does the media prefer PRGO or NKTR?

Which has more risk and volatility, PRGO or NKTR?

Summary

How does Perrigo compare to Pacira BioSciences?

Is PRGO or PCRX more profitable?

Do analysts prefer PRGO or PCRX?

Which has more volatility & risk, PRGO or PCRX?

Do insiders and institutionals hold more shares of PRGO or PCRX?

Does the media refer more to PRGO or PCRX?

Which has better earnings & valuation, PRGO or PCRX?

Summary

How does Perrigo compare to Omeros?

Which has more risk and volatility, OMER or PRGO?

Does the media prefer OMER or PRGO?

Do analysts recommend OMER or PRGO?

Do insiders and institutionals have more ownership in OMER or PRGO?

Is OMER or PRGO more profitable?

Which has better earnings & valuation, OMER or PRGO?

Summary

How does Perrigo compare to Assembly Biosciences?

Which has better valuation & earnings, PRGO or ASMB?

Do analysts recommend PRGO or ASMB?

Is PRGO or ASMB more profitable?

Do insiders and institutionals believe in PRGO or ASMB?

Does the media refer more to PRGO or ASMB?

Which has more volatility & risk, PRGO or ASMB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRGO vs. The Competition

Perrigo Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools